Benjamin Besse
@benjaminbessemd
Medical Oncologist- Lung cancer, thymic & NUT carcinomas. Head of Clinical Research @GustaveRoussy, Head of Scientific Chairs Council @EORTC. Tweets are my own.
ID: 2997824224
25-01-2015 13:13:03
347 Tweet
7,7K Followers
91 Following
Pr Egbert Smit elegantly suggests that TROP-2 ADCs with a topo-1 inhibitor payload (deruxtecan, govitecan…) are not better that old fashioned topo-1 inhibitors such as irinotecan or topotecan.
